Abstract

Controlled macrophage differentiation and activation in the initiation and resolution of inflammation is crucial for averting progression to chronic inflammatory and autoimmune diseases. Here we show a negative feedback mechanism for proinflammatory IFN-γ activation of macrophages driven by macrophage-associated matrix metalloproteinase 12 (MMP12). Through C-terminal truncation of IFN-γ at 135Glu↓Leu136 the IFN-γ receptor-binding site was efficiently removed thereby reducing JAK-STAT1 signaling and IFN-γ activation of proinflammatory macrophages. In acute peritonitis this signature was absent in Mmp12–/– mice and recapitulated in Mmp12+/+ mice treated with a MMP12-specific inhibitor. Similarly, loss-of-MMP12 increases IFN-γ–dependent proinflammatory markers and iNOS+/MHC class II+ macrophage accumulation with worse lymphadenopathy, arthritic synovitis and lupus glomerulonephritis. In active human systemic lupus erythematosus, MMP12 levels were lower and IFN-γ higher compared to treated patients or healthy individuals. Hence, macrophage proteolytic truncation of IFN-γ attenuates classical activation of macrophages as a prelude for resolving inflammation.

Details

Title
C-terminal truncation of IFN-γ inhibits proinflammatory macrophage responses and is deficient in autoimmune disease
Author
Dufour, Antoine 1 ; Bellac, Caroline L 2 ; Ulrich, Eckhard 3   VIAFID ORCID Logo  ; Solis, Nestor 3 ; Klein, Theo 3   VIAFID ORCID Logo  ; Kappelhoff, Reinhild 3 ; Fortelny, Nikolaus 4 ; Parker Jobin 4 ; Rozmus, Jacob 5 ; Mark, Jennifer 3 ; Pavlidis, Paul 6 ; Dive, Vincent 7 ; Barbour, Sean J 8 ; Overall, Christopher M 4   VIAFID ORCID Logo 

 Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, BC, Canada; Centre for Blood Research, Vancouver, BC, Canada; Department of Physiology and Pharmacology McCaig Institute for Bone and Joint Health, Cumming School of Medicine, Dr NW Calgary, AB, Canada 
 Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, BC, Canada; Centre for Blood Research, Vancouver, BC, Canada; Swissmedic, Swiss Agency for Therapeutics Products, Bern 9, Switzerland 
 Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, BC, Canada; Centre for Blood Research, Vancouver, BC, Canada 
 Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, BC, Canada; Centre for Blood Research, Vancouver, BC, Canada; Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada 
 Department of Pediatrics, Child and Family Research Institute and BC Children’s Hospital, University of British Columbia, Vancouver, BC, Canada 
 Centre for High Throughput Biology, University of British Columbia, Vancouver, BC, Canada; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada 
 Commissariat a l’Energie Atomique (CEA) CE-Saclay, Labex LERMIT, Service d’Ingenierie Moleculaire des Proteines, Gif/Yvette, France 
 Department of Medicine, University of British Columbia, Vancouver, BC, Canada 
Pages
1-18
Publication year
2018
Publication date
Jun 2018
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2057428669
Copyright
© 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.